These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 31534006

  • 1. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q, Wang HY, Liu X, Nunez-Cruz S, Jillab M, Melnikov O, Nath K, Glickson J, Wasik MA.
    J Immunol; 2019 Oct 15; 203(8):2043-2048. PubMed ID: 31534006
    [Abstract] [Full Text] [Related]

  • 2. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.
    Thieme E, Liu T, Bruss N, Roleder C, Lam V, Wang X, Nechiporuk T, Shouse G, Danilova OV, Bottomly D, McWeeney SK, Tyner JW, Kurtz SE, Danilov AV.
    Cell Death Dis; 2022 Mar 16; 13(3):246. PubMed ID: 35296646
    [Abstract] [Full Text] [Related]

  • 3. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M.
    Mol Cancer Ther; 2019 Feb 16; 18(2):267-277. PubMed ID: 30413649
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
    Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.
    Int J Cancer; 2015 Jun 15; 136(12):2761-74. PubMed ID: 25388373
    [Abstract] [Full Text] [Related]

  • 5. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
    Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S.
    Cancer Discov; 2014 Sep 15; 4(9):1022-35. PubMed ID: 25082755
    [Abstract] [Full Text] [Related]

  • 6. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F, Liu Y, Liu M, Zhang D, Wang P, Dong J, Tang W, Zhao G.
    Bioorg Chem; 2019 Aug 15; 89():102943. PubMed ID: 31031018
    [Abstract] [Full Text] [Related]

  • 7. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
    Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S.
    Leuk Res; 2013 Oct 15; 37(10):1271-7. PubMed ID: 23962569
    [Abstract] [Full Text] [Related]

  • 8. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, Jessen KA, Lannutti BJ, Wang M.
    J Hematol Oncol; 2021 Aug 28; 14(1):132. PubMed ID: 34454548
    [Abstract] [Full Text] [Related]

  • 9. The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma.
    Lantermans HC, Ma F, Kuil A, van Kesteren S, Yasinoglu S, Yang G, Buhrlage SJ, Wang J, Gray NS, Kersten MJ, Treon SP, Pals ST, Spaargaren M.
    Leukemia; 2024 Jul 28; 38(7):1570-1580. PubMed ID: 38454120
    [Abstract] [Full Text] [Related]

  • 10. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
    Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J.
    Oncotarget; 2015 Jun 20; 6(17):15122-36. PubMed ID: 25944695
    [Abstract] [Full Text] [Related]

  • 11. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
    Ran F, Liu Y, Yu S, Guo K, Tang W, Chen X, Zhao G.
    Bioorg Chem; 2020 Jan 20; 94():103367. PubMed ID: 31685258
    [Abstract] [Full Text] [Related]

  • 12. Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
    Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD, Wasik MA.
    Mol Cancer Res; 2019 Jun 20; 17(6):1365-1377. PubMed ID: 30862686
    [Abstract] [Full Text] [Related]

  • 13. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
    Ran F, Liu Y, Chen X, Zhuo H, Xu C, Li Y, Duan X, Zhao G.
    Bioorg Chem; 2021 Jul 20; 112():104968. PubMed ID: 34000704
    [Abstract] [Full Text] [Related]

  • 14. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.
    Clin Cancer Res; 2016 Jun 01; 22(11):2684-96. PubMed ID: 26819453
    [Abstract] [Full Text] [Related]

  • 15. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL.
    Br J Haematol; 2014 Sep 01; 166(6):849-61. PubMed ID: 24957109
    [Abstract] [Full Text] [Related]

  • 16. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK.
    Curr Med Chem; 2024 Sep 01; 31(30):4757-4762. PubMed ID: 37818564
    [Abstract] [Full Text] [Related]

  • 17. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.
    Blood; 2017 Feb 09; 129(6):759-770. PubMed ID: 28011673
    [Abstract] [Full Text] [Related]

  • 18. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
    Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A.
    Blood; 2016 Jul 07; 128(1):82-92. PubMed ID: 27127301
    [Abstract] [Full Text] [Related]

  • 19. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.
    Ahmed M, Lorence E, Wang J, Jung D, Zhang L, Nomie K, Wang M.
    Sci Signal; 2019 Feb 05; 12(567):. PubMed ID: 30723172
    [Abstract] [Full Text] [Related]

  • 20. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
    Wu X, Nowakowski KE, Abeykoon JP, Manske M, Stenson MJ, Timm MM, Hanson CA, Van Dyke DL, Dasari S, Witzig TE.
    Eur J Haematol; 2021 Oct 05; 107(4):458-465. PubMed ID: 34214199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.